Yahoo Sports' Andy Behrens and Scott Pianowski talk about the explosion of dual-threat QBs in the NFL, including why they are so important when it comes to fantasy football.
Yahoo Sports' Andy Behrens and Scott Pianowski talk about the explosion of dual-threat QBs in the NFL, including why they are so important when it comes to fantasy football.
The Optical Microscopes Market will grow by $557.96 mn during 2020-2024
Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced the launch of an Infosys Cobalt offering - its applied AI cloud, built on NVIDIA DGXTM A100 systems, the universal system for all AI workloads, offering unprecedented compute density, performance, and flexibility. The powerful new Infosys applied AI cloud will be an AI center of excellence for the company, enabling developers and project teams at Infosys to quickly and easily access AI hardware and software stacks, across both private and public clouds, to build contextualized services that deliver AI-first business processes for enterprises. NVIDIA DGX A100 systems will provide the infrastructure and the advanced compute power needed for over 100 project teams to run machine learning and deep learning operations, simultaneously. NVIDIA Multi-Instance GPU (MIG) technology will enable Infosys to improve infrastructure efficiency and maximize utilization of each DGX A100 system. Teams can process AI algorithms centrally or locally on any device, without lag, using Infosys edge AI.
Investors are flocking to ESG (environmental, social, and governance) funds in particular, dumping a net $97 billion into ESG ETFs and sparking the launch of some 200 new ESG ETFs in 2020 alone. Why have ESG funds become so popular? As a broader point of comparison, the S&P 500 ESG index has outperformed the standard S&P 500 index over the last one-year, three-year, and five-year time frames.
Aerial Imaging Market Research Report by Type (Drone Imagery, Infrared Radiation, Panchromatic, Radar Imagery, and Spectrazonal Imagery), by Imaging Type (Oblique imaging and Vertical imaging), by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Aerial Imaging Market Research Report by Type, by Imaging Type, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06007535/?utm_source=GNW Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Aerial Imaging Market is expected to grow from USD 2,038.42 Million in 2020 to USD 3,385.53 Million by the end of 2025.2. The Global Aerial Imaging Market is expected to grow from EUR 1,787.33 Million in 2020 to EUR 2,968.50 Million by the end of 2025.3. The Global Aerial Imaging Market is expected to grow from GBP 1,588.94 Million in 2020 to GBP 2,639.00 Million by the end of 2025.4. The Global Aerial Imaging Market is expected to grow from JPY 217,551.95 Million in 2020 to JPY 361,322.28 Million by the end of 2025.5. The Global Aerial Imaging Market is expected to grow from AUD 2,960.06 Million in 2020 to AUD 4,916.24 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Aerial Imaging to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Type, the Aerial Imaging Market studied across Drone Imagery, Infrared Radiation, Panchromatic, Radar Imagery, Spectrazonal Imagery, and Thermal Imagery. Based on Imaging Type, the Aerial Imaging Market studied across Oblique imaging and Vertical imaging. Based on Application, the Aerial Imaging Market studied across Conservation & Research, Disaster Management, Energy & Resource Management, Geospatial Mapping, Surveillance & Monitoring, and Urban Planning. Based on End User, the Aerial Imaging Market studied across Agriculture & Forestry, Civil Engineering & Archaeology, Energy & Utilities, Government & Public Safety, Media & Entertainment, and Military & Defense. "The Asia-Pacific is projected to witness the highest growth during the forecast period"Based on Geography, the Aerial Imaging Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Aerial Imaging Market in 2020. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Aerial Imaging Market including 3D Robotics, Inc., AeroVironment, Inc., Airobotics Ltd., Blom Norway AS, Cooper Aerial Surveys Co., Digital Aerial Solutions LLC, Dronedeploy Inc., Eagle Aerial Imaging Inc., EagleView Technologies, Inc., Equinox’s Drones Pvt Ltd, Fugro EarthData, Inc., Fugro N.V., Getmapping PLC, Global UAV Technologies Ltd., Hoverfly Technologies, Inc, Kucera International Inc., Landiscor Real Estate Mapping, Nearmap Ltd, PrecisionHawk, and senseFly SA by Parrot Group. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.360iResearch™ FPNV Positioning Matrix:The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the Aerial Imaging Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.360iResearch™ Competitive Strategic Window:The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Aerial Imaging Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Aerial Imaging Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Aerial Imaging Market?4. What is the competitive strategic window for opportunities in the Global Aerial Imaging Market?5. What are the technology trends and regulatory frameworks in the Global Aerial Imaging Market?6. What are the modes and strategic moves considered suitable for entering the Global Aerial Imaging Market?Read the full report: https://www.reportlinker.com/p06007535/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
The BlackNorth Initiative is proud to announce that Wes Hall, its Founder and Chairman, has been named to the 2021 Maclean’s Power List, as one of the most influential people in Canada.
Alexco Resource Corp. (NYSE American: AXU) (TSX: AXU) ("Alexco" or the "Company) today reported results from its 2020 surface exploration drilling program that focused on the Bermingham Northeast Deep zone located at depth approximately 150 meters ("m") below the existing mineral resource, that is currently in development for ore production beginning in the second quarter of 2021. The Company also provided a brief update on Keno Hill Operations and Corporate activity.
The 47-year-old occupied one of the automatic places in the team before the golf was stopped due to Covid-19.
Using only routinely collected information, this tool can accurately determine whether a COVID patient's condition is likely to deteriorate.
Pier 4 is the first multi-tenant office building in the city to use virtual reality to conduct fire drills. With many people working from home due to the COVID-19 pandemic, CommonWeath Partners opted to deploy virtual reality technology to help ensure all occupants know how to respond in an emergency whenever they are in the office.
Array, a leading content engagement solution provider for life sciences events, announced today that it has changed its name from Educational Measures® and focused its vision for the company going forward. The change consolidates the brand around the company's Array content engagement software and services which have been used to increase audience engagement at over 7,000 life sciences events. Along with the new name, the company has debuted updated product branding and a new website at www.ArrayLive.com. The new look and messaging reflect the company's focus on life sciences industry events and its commitment to helping clients create meaningful events that improve patient outcomes.
The bank has named the branches that will close between April and September, but aims to avoid redundancies.
Stuck for ideas on how to socialise during lockdown? These group activities will keep everyone entertained
Crystal Capital Partners releases web-based alternative investment proposals to help financial advisors modernize their client prospecting efforts.
BEVERLY, Mass. and TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it has appointed Marc Robinson to the Board as an independent director, effective January 19, 2021. “We are delighted to have Marc join our Board of Directors,” said David Wolf, President and Chief Executive Officer. “As Hamilton Thorne continues to grow and evolve, it is important to add new voices and experience that will support our continued development over the next decade. We look forward to Marc’s advice and support as Hamilton Thorne continues growing its business.” Mr. Robinson currently serves as Managing Director, Investments at FAX Capital Corp. FAX Capital is a TSX listed holding company, focused on making long-term investments in high-quality public and private growth companies, and currently holds an 11.5% interest in Hamilton Thorne. Mr. Robinson is a seasoned executive with over 20 years of experience across various facets of the North American capital markets and has a demonstrable track record of successfully financing and advising high growth companies. Mr. Robinson has previously worked as a small-cap portfolio manager and was awarded the Lipper Award for Best 3-Year Performance, Canadian Focused Small/Mid Cap Equity in 2018. Previously, Mr. Robinson was an established equity research analyst at a leading Canadian small-cap focused investment dealer, where he also sat on the firm’s executive and risk committees, and worked as an investment banker at Merrill Lynch. Diarmaid Douglas-Hamilton, a co-founder of Hamilton Thorne and its Chief Technology Officer, will retire from the Board of Directors but will continue to stay active with the Company. Mr. Wolf continued, “I would like to personally thank and recognize Diarmaid for his significant and continued contributions to the Company’s growth. As a leader in our research and development group, he has a significant track record of innovation and has been the primary driver behind a number of Hamilton Thorne’s proprietary products.” At FAX Capital, Mr. Robinson continues to drive its operational strategy and has directed investment decisions since the company’s inception. Mr. Robinson holds a Bachelor’s degree in Statistics from the University of Western Ontario and an Honours and Master’s degree in Business from the Richard Ivey School of Business. About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd) Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments. Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release. Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com. For more information, please contact: David Wolf, President & CEOMichael Bruns, CFOGlen AkselrodHamilton Thorne Ltd.Hamilton Thorne Ltd.Bristol Investor Relations978firstname.lastname@example.org@email@example.com
The ODP Corporation outlines path forward for value creation in letter to Sycamore Partners, owner of Staples
The "Vaccine transport and logistics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
Nephrology Associates of Northern Illinois and Indiana (NANI), the largest Nephrology group in the United States, is the first practice in Illinois to adopt the Ellipsys® Vascular Access System, a revolutionary technology that provides easier access to the bloodstream for patients with end-stage renal disease (ESRD) who require life-saving hemodialysis treatments.
Telco Systems, the leading provider of innovative SDN/NFV, CE 2.0, MPLS and IP solutions, today announced that the company has upgraded its NFVTime uCPE and Edge Compute solution to support public Cloud environments, including Amazaon Web Services (AWS) and Microsoft Azure.
Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D.AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders who specialize in cerebrovascular diseases including ischemic stroke, which is the third leading cause of death and second leading cause of disability in the world. The CMAB is chaired by Clay Johnston, M.D., Ph.D., Dean of Dell Medical School, Vice President for Medical Affairs, University of Texas, Austin. Members of the board include Greg Albers, M.D., Director of Stanford University Stroke Center, and Brett Cucchiara, M.D., Director of the Neurovascular Ultrasound Laboratory at the University of Pennsylvania. The CMAB is providing expert Medical and Clinical guidance for XBiotech’s new candidate neuroprotectant, anti-inflammatory True Human™ antibody therapy to treat stroke. Dr. Clay Johnston commented, “While we have done a great job in increasing reperfusion after stroke, we have failed to address the downstream injury that nearly always occurs. Inflammation is a key part of that injury and blocking IL-1⍺ has real potential in further improving outcomes for patients. Once again, I’m excited about the potential for a neuroprotective agent.” Together with the CMAB, the Company believes it has the potential to provide groundbreaking antibody therapies to patients that will help reduce the impact of strokes and improve recovery of stroke victims. Currently, no neuroprotectant treatment has been approved for the damaging effects of reperfusion injury, representing an extraordinary unmet medical need. John Simard, President and CEO of XBiotech, commented, “I am indeed honored to have the support of such distinguished medical experts assisting XBiotech in developing a True Human antibody which we believe has unprecedented potential as a neuroprotectant for patients who experience ischemic strokes. We plan to expedite clinical development of this unique new drug.” XBiotech’s Cerebrovascular Medical Advisory Board Includes: Clay Johnston M.D., Ph.D. currently serves as the inaugural dean of Dell Medical School at the University of Texas in Austin. As a neurologist specializing in stroke care and research, he has published extensively in the prevention and treatment of stroke and transient ischemic attack. He has led several large cohort studies and three international multi-center randomized trials. Dr. Johnston is a graduate of Amherst College and Harvard Medical School. He later received his Ph.D. in epidemiology from the University of California, Berkeley, and was a resident in Neurology at UCSF, where he trained in Vascular Neurology. Dr. Johnston has received national accolades for his research and was elected to the National Academy of Medicine in 2019.Greg W. Albers, M.D. is a stroke and vascular neurologist and currently serves as the Director of the Stanford Stroke Center at Stanford Medical Center. Dr. Albers is a Coyote Foundation Professor and a Professor, by courtesy, of Neurosurgery and Neurological Sciences at Stanford University. Dr. Albers’ primary research focus is the diagnosis, management, and prevention of ischemic stroke. A prolific and distinguished researcher, he has authored more than 450 articles on topics related to cerebrovascular disease in peer-reviewed journals. Brett L. Cucchiara M.D. is a Professor of Neurology and serves as the Director of the Neurovascular Ultrasound Laboratory at the University of Pennsylvania. He specializes in cerebrovascular disease and has extensive experience in stroke clinical trials and biomarker research. Dr. Cucchiara is a member of the American Board of Psychiatry and Neurology. Brain reperfusion, or opening of the clogged artery, is the cornerstone of emergency treatment for ischemic stroke. However, opening of a clogged artery is associated with a rapid induction of inflammation where the returning blood supply downstream of the clogged artery begins to recirculate in the brain. The brain injury inflicted by the inflammation can be devastating. There is presently no approved drug to reduce injury from reperfusion. XBiotech previously announced a publication, in animal models of stroke, which described a significant reduction in brain injury when an IL-1⍺ neutralizing antibody was used to inhibit inflammation prior to unblocking of the clogged artery. On December 30, 2019, XBiotech sold a True Human™ anti-inflammatory antibody in a $1.35 billion transaction. The Company has since worked vigorously to bring a new line of True Human™ anti-inflammatory therapies to the clinic in 2021. XBiotech is now developing a novel True Human™ antibody therapy that neutralizes interleukin-1 alpha (IL-1⍺) as a neuroprotectant. IL-1⍺ is a trigger in the onset of inflammation. When inflammation is deregulated, or in situations of acute injury, such as that which occurs after reperfusion (the resumption of blood flow after unblocking of an artery), IL-1⍺ enhances the inflammation that leads to worsening of the injury. About XBiotechXBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. XBiotech currently is advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases. Utilizing natural human immunity as a source of new medicines offers the potential to redefine the standards of care for a wide range of diseases. On December 30, 2019 XBiotech sold an IL-1⍺ blocking True Human™ antibody that had been used successfully in a number of clinical trials. The sale of the antibody generated $750 million in upfront cash and up to $600 million in potential milestone payments. The Company retained the right to pursue the development of True Human™ antibodies targeting IL-1⍺ for all areas of medicine outside of dermatology. While the Company previously was focused on a single True Human™ antibody targeting IL-1⍺, it now plans to develop multiple product candidates, which will target IL-1⍺ in specific areas of medicine. In addition to recent sale of its anti-IL-1⍺ antibody, XBiotech now has other revenue sources. Commencing January 1, 2020 XBiotech began using its proprietary manufacturing technology to produce clinical drug product for a major Pharmaceutical Company under a two-year supply agreement. In addition, XBiotech is providing clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The financial strength generated from the sale and contract operations is enabling XBiotech to expand both its anti-IL-1⍺ product development and infectious disease programs. To accelerate advance of the Company’s pipeline, the Company is expanding its existing manufacturing and research center, and planning to build an additional 30,000ft2 infectious disease research & development center on its 48-acre property in Austin, TX which is wholly owned by the Company. The expansion and new building will be in addition to the present custom-built 33,000ft2 combined manufacturing and R&D facility that currently exists on the campus. XBiotech owns the 48-acre campus—and all structures on the property—debt-free and envisions further expansion of facilities. For more information, visit www.xbiotech.com. About True Human™ Therapeutic AntibodiesXBiotech’s True Human™ antibodies are the only available antibodies derived without modification from humans who possess natural immunity to certain diseases. (Unlike all commercially available antibodies, which are called “Humanized” or “Fully Human”, XBiotech’s True Human™ antibodies are directly sourced from the natural human immune response for specific diseases without modification, and thereby have not been shown to cause immunogenicity.) With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability. Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Ashley Oteroaotero@xbiotech.com512-386-2930
Baby Sleep Miracle is an ebook providing knowledge about how to calm a baby and put her/him to sleep. According to the publishers, this ebook has become a bestseller among new parents. The reasons are, this ebook is easy to read, and the suggestions are simple for the parents to follow. Dealing with a baby with a sleep disorder is a part of parenthood. Many parents keep their babies awake till late, hoping that the baby will fall asleep then. But according to Mary Ann, author of Baby Sleep Miracle, this is a myth. A baby should have a fixed bedtime, and that will differ with the age of the baby. Mary Ann has discussed many such tips to put a baby to sleep in the ebook. Mary Ann, who is a mother of two children, has put together her experiences and science in the book for the benefit of other parents. The strategies discussed by her cover every type of child, active or stubborn, can be calmed using the instructions given in the book.